D. Christ

发表

Discovery of γ-Lactam Hydroxamic Acids as Selective Inhibitors of Tumor Necrosis Factor α Converting Enzyme: Design, Synthesis, and Structure−Activity Relationships

Chen Lihua, Zelda R. Wasserman, Karl D. Hardman, 2002 .

The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats.

G T Miwa, R. Robertson, A. Mutlib, 2000, Toxicology and applied pharmacology.

Losartan (DuP 753), An Orally Active Nonpeptide Angiotensin II Receptor Antagonist

P. Timmermans, J. Duncia, D. Christ, 1991 .

Pharmacokinetics and Pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-Amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a Potent and Selective Inhibitor of Tumor Necrosis Factor α-Converting Enzyme in Rodents, Dogs, Chimpanzees, and Humans

J. Trzăskos, T. Maduskuie, C. Garner, 2007, Drug Metabolism and Disposition.

The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1 ,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist.

G. Trainor, A. Cocuzza, D. Robertson, 2000, Bioorganic & medicinal chemistry.

Development of a Dog Microdialysis Model for Determining Synovial Fluid Pharmacokinetics of Anti-Arthritis Compounds Exemplified by Methotrexate

M. Qian, D. Christ, Jing-tao Wu, 2003, Pharmaceutical Research.

N-in-1 dosing pharmacokinetics in drug discovery: experience, theoretical and practical considerations.

P. Lam, K. He, T. Olah, 2008, Journal of pharmaceutical sciences.

Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.

R. Magolda, M. Covington, C. Decicco, 2001, Journal of medicinal chemistry.

Potent P1' biphenylmethyl substituted aggrecanase inhibitors.

M. Covington, C. Decicco, R. Wexler, 2002, Bioorganic & medicinal chemistry letters.

Human anti-endoplasmic reticulum antibodies in sera of patients with halothane-induced hepatitis are directed against a trifluoroacetylated carboxylesterase.

B. Martin, H. Satoh, L. Pohl, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Liquid chromatography/mass spectrometry and high-field nuclear magnetic resonance characterization of novel mixed diconjugates of the non-nucleoside human immunodeficiency virus-1 reverse transcriptase inhibitor, efavirenz.

A. Mutlib, D. Christ, H. Chen, 1999, Drug metabolism and disposition: the biological fate of chemicals.

Metabolic basis for a drug hypersensitivity: antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane.

H. Satoh, L. Pohl, J. G. Kenna, 1988, The Journal of pharmacology and experimental therapeutics.

Potential metabolic basis for enflurane hepatitis and the apparent cross-sensitization between enflurane and halothane.

H. Satoh, L. Pohl, J. G. Kenna, 1988, Drug metabolism and disposition: the biological fate of chemicals.

CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity.

I. Kariv, K. Vaddi, M. Covington, 2007, Bioorganic & medicinal chemistry letters.

Nonpeptide Angiotensin II Receptor Antagonist: Losartan

R. Lee, J. Duncia, R. Wexler, 1993 .

Enflurane metabolism produces covalently bound liver adducts recognized by antibodies from patients with halothane hepatitis.

H. Satoh, L. Pohl, J. G. Kenna, 1988 .

Toxicokinetics and Drug Disposition

D. Christ, 2018, Toxicologic Pathology.

The immunologic and metabolic basis of drug hypersensitivities.

H. Satoh, L. Pohl, J. G. Kenna, 1988, Annual review of pharmacology and toxicology.

The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dog.

Y. Wong, D. Christ, P. Wong, 1994, The Journal of pharmacology and experimental therapeutics.

Mass spectrometric and NMR characterization of metabolites of roxifiban, a potent and selective antagonist of the platelet glycoprotein IIb/IIIa receptor

A. Mutlib, J. Shockcor, S. Diamond, 2000, Xenobiotica; the fate of foreign compounds in biological systems.

Alpha,Beta-cyclic-beta-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).

J. Trzăskos, W. Marshall, K. Vaddi, 2008, Bioorganic & medicinal chemistry letters.

4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.

S. Shelton, G. Trainor, P. Hartig, 2000, Journal of medicinal chemistry.

Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.

D. J. Nelson, K. D. Hardman, R. Copeland, 2001, Journal of medicinal chemistry.

Potent and selective aggrecanase inhibitors containing cyclic P1 substituents.

R. Magolda, J. Trzăskos, M. Covington, 2003, Bioorganic & medicinal chemistry letters.

Neoantigens associated with halothane hepatitis.

H. Satoh, L. Pohl, J. G. Kenna, 1989, Drug metabolism reviews.

Enhancement of losartan (DuP 753)-induced angiotensin II receptor antagonism by PD123177 in rats.

P. Timmermans, D. Christ, P. Wong, 1992, European journal of pharmacology.

Human Plasma Protein Binding of the Angiotensin II Receptor Antagonist Losartan Potassium (DuP 753/MK 954) and Its Pharmacologically Active Metabolite EXP3174

D. Christ, 1995, Journal of clinical pharmacology.

Separation of the enantiomers of intact sulfate conjugates of adrenergic drugs by high-performance liquid chromatography after chiral derivatization.

T. Walle, D. Christ, M. Wilson, 1985, Journal of chromatography.

Chapter 33. Plasma Protein Binding of Drugs

David D. Christ, R. Olson, D. Christ, 1996 .

α,β-Cyclic-β-benzamido hydroxamic acids: Novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-α converting enzyme (TACE)

David D. Christ, K. Vaddi, M. Covington, 2008 .

Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors.

Zelda R Wasserman, J. Trzăskos, K. Vaddi, 2008, Bioorganic & medicinal chemistry letters.

Potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE): discovery of indole, benzofuran, imidazopyridine and pyrazolopyridine P1' substituents.

J. Trzăskos, K. Vaddi, M. Covington, 2008, Bioorganic & medicinal chemistry letters.

Design, Synthesis, and Evaluation of Benzothiadiazepine Hydroxamates as Selective Tumor Necrosis Factor-α Converting Enzyme Inhibitors

S. Mandlekar, K. D. Hardman, R. Magolda, 2003 .

Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.

J. Trzăskos, K. Vaddi, M. Covington, 2008, Bioorganic & medicinal chemistry letters.

A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.

J. Trzăskos, Xiao-tao Chen, K. Vaddi, 2007, Bioorganic & medicinal chemistry letters.

In Vitro and In Vivo Effects of the Arylamine Human Immunodeficiency Virus Protease Inhibitor 4R-(4α,5α,6β,7β)-1-[(3-(1-Imidazoylcarbamoyl)phenyl)methyl]-3-[(3-aminophenyl)methyl]hexahydro-5,6-dihydroxy-4,7-bis(phenylmethyl)-2H-1,3-diazepin-2-one (SD894) on Rat Hepatic Cytochrome P450 2B and 3A

S. Diamond, D. Christ, M. Grubb, 1997 .

Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.

S. Mandlekar, K. D. Hardman, R. Magolda, 2003, Journal of medicinal chemistry.

The discovery and development of angiotensin II antagonists.

J. Duncia, D. Christ, M. Pierce, 1998, Pharmaceutical biotechnology.

Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz.

A. Mutlib, D. Christ, H. Chen, 1999, Drug metabolism and disposition: the biological fate of chemicals.

Enflurane Metabolism Produces Covalently Bound Liver Adducts Recognized by Antibodies from Patients with Halothane Hepatitis

H. Satoh, L. Pohl, J. G. Kenna, 1988, Anesthesiology.

CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes.

Sean Kim, Kathy Carroll, Mark Cunningham, 2002, Drug metabolism and disposition: the biological fate of chemicals.

Interaction of ritonavir on tissue distribution of a [(14)c]L-valinamide, a potent human immunodeficiency virus-1 protease inhibitor, in rats using quantitative whole-body autoradiography.

S. Diamond, D. Christ, L. Gan, 2002, Drug metabolism and disposition: the biological fate of chemicals.

Pharmacokinetics and metabolism of the pharmacologically active 4'-hydroxylated metabolite of propranolol in the dog.

T. Walle, D. Christ, U. Walle, 1990, Drug metabolism and disposition: the biological fate of chemicals.

Sultam hydroxamates as novel matrix metalloproteinase inhibitors.

K. D. Hardman, J. Trzăskos, M. Covington, 2004, Journal of medicinal chemistry.

Glucuronidation in the chimpanzee (Pan troglodytes): Studies with acetaminophen, oestradiol and morphine

H. Wong, D. Christ, S. Grossman, 2006, Xenobiotica; the fate of foreign compounds in biological systems.

Cassette dosing pharmacokinetics: valuable tool or flawed science?

D. Christ, D D Christ, 2001, Drug metabolism and disposition: the biological fate of chemicals.

Design, Synthesis, and Structure−Activity Relationships of Macrocyclic Hydroxamic Acids That Inhibit Tumor Necrosis Factor α Release in Vitro and in Vivo

Chen Lihua, Robert A. Copeland, David J. Nelson, 2001 .

THE CHIMPANZEE (PAN TROGLODYTES) AS A PHARMACOKINETIC MODEL FOR SELECTION OF DRUG CANDIDATES: MODEL CHARACTERIZATION AND APPLICATION

K. He, H. Wong, S. Diamond, 2004, Drug Metabolism and Disposition.

Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859).

T. Graczyk, Michael Koblish, R. Dolle, 2008, Journal of medicinal chemistry.

The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Francisella tularensis SCHU S4 Infection in BALB/c Mice and Cynomolgus Macaques

V. Tam, T. Grossman, D. Christ, 2017, Antimicrobial Agents and Chemotherapy.

Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.

R. Magolda, J. Trzăskos, K. Vaddi, 2004, Bioorganic & medicinal chemistry letters.

Stereoselective sulfate conjugation of 4-hydroxypropranolol in vitro by different species.

T. Walle, D. Christ, 1985, Drug Metabolism And Disposition.

Monoclonal antibodies to the nonpeptide angiotensin II receptor antagonist, losartan.

P. Timmermans, S. Pierce, T. Reilly, 1992, European journal of pharmacology.

Stereoselective sulfation of R,S-4'-hydroxypropranolol by canine hepatic cytosol and partially purified phenolsulfotransferases.

T. Walle, D. Christ, 1989, The Journal of pharmacology and experimental therapeutics.

Induction of cytochromes P-450 2B and 3A in mice following the dietary administration of the novel cognitive enhancer linopirdine.

S. Diamond, D. Christ, J. O'Neil, 1994, Drug metabolism and disposition: the biological fate of chemicals.

Species-specific, P450- and sulfotransferase-mediated novel ring contraction of a naphthyridine-N-oxide compound in cynomolgus monkey.

A. Mutlib, S. Unger, Barry C. Johnson, 2007, Chemical research in toxicology.

Nonpeptide angiotensin II receptor antagonist: pharmacokinetics and pharmacodynamics in rats of EXP3174, an active metabolite of losartan.

Y. Wong, D. Christ, P. Wong, 1996, Pharmacology.

Synthesis and biological activities of potential metabolites of the non-nucleoside reverse transcriptase inhibitor efavirenz.

A. Mutlib, S. P. Seitz, R. Klabe, 2001, Bioorganic & Medicinal Chemistry Letters.